摘要
IntroductionThiopurines, azathiopurine (AZA) and mercaptopurine (6-MP) have been regularly used in the treatment of inflammatory bowel disease (IBD). Despite optimized dosage adjustment based on the NUDT15 genotypes, some patients still discontinue or change treatment regimens due to thiopurine-induced leukopenia. MethodsWe proposed a prospective observational study of lipidomics to reveal the lipids perturbations associated with thiopurine-induced leukopenia. One hundred and twenty-seven IBD participants treated with thiopurine were enrolled, twenty-seven of which have developed thiopurine-induced leucopenia. Plasma lipid profiles were measured using Ultra-High-Performance Liquid Chromatography-Tandem Q-Exactive. Lipidomic alterations were validated with an independent validation cohort (leukopenia n = 26, non-leukopenia n = 74). ResultsUsing univariate and multivariate analysis, there were 16 lipid species from four lipid classes, triglyceride (n = 11), sphingomyelin (n = 1), phosphatidylcholine (n = 1) and lactosylceramide (n = 3) identified. Based on machine learning feature reduction and variable screening strategies, the random forest algorithm established by six lipids showed an excellent performance to distinguish the leukopenia group from the normal group, with a model accuracy of 95.28% (discovery cohort), 79.00% (validation cohort) and an area under the receiver operating characteristic (ROC) curve (ROC-AUC) of 0.9989 (discovery cohort), 0.8098 (validation cohort). DiscussionOur novel findings suggested that lipidomic provided unique insights into formulating individualized medication strategies for thiopurines in IBD patients.
学科与关键词
- UPLC-QTOF-MS-Based Plasma Lipidomic Profiling Reveals Biomarkers for Inflammatory Bowel Disease DiagnosisGuan, Su; Jia, Bingjie; Chao, Kang; Zhu, Xia; Tang, Jian; Li, Miao; Wu, Lvying; Xing, Lei; Liu, Kun; Zhang, Lei; Wang, Xueding; Gao, Xiang*; Huang, Min*Journal of Proteome Research, 2020, 19(2): 600-609.被引 38
- Association between the use of lipid-lowering drugs and the risk of inflammatory bowel diseaseLiu, Xuxu; Lv, Zhenyi; Xie, Zhihong; Wang, Qiang; Yao, Wenchao; Yu, Jingjing; Jing, Qingxu; Meng, Xianzhi; Ma, Biao; Xue, Dongbo*; Hao, Chenjun*European Journal of Clinical Investigation, 2023, 53(12): e14067.被引 1
- Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker IdentificationTitz, Bjoern*; Gadaleta, Raffaella M.; Lo Sasso, Giuseppe; Elamin, Ashraf; Ekroos, Kim; Ivanov, Nikolai V.; Peitsch, Manuel C.; Hoeng, Julia*INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19(9): 2775.被引 33
